Liquidia Corporation kompaniyasidagi eng so‘nggi ish o‘rinlari

Liquidia Corporation is a biopharmaceutical company developing inhaled treatments for rare cardiopulmonary conditions, with a focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its PRINT® particle engineering technology is used to design drug formulations and delivery methods for inhaled medicines. The company’s portfolio includes inhaled treprostinil and the clinical-stage candidate L606, alongside work in clinical development and patient support.